The clinical spectrum associated with ERCC5 mutations: Is there a relationship between phenotype and genotype?

Abstract

Mutations in the ERCC5 gene can lead to different clinical phenotypes, few articles have reported the clinical phenotypes in detail and explained the relationship between genotype and phenotype. The clinical data of cases with ERCC5 gene mutations diagnosed in our center and reported in previous studies were collected. The cases were divided into three groups based on phenotype; the differences of clinical manifestation and genotype among groups were analyzed. Genetic tests showed a complex heterozygous mutation of the ERCC5 gene with paternal C.402_C.403 (exon 4) insA (p.T135Nfs*28) and maternal C.1096 (exon 8) C > T (p.R366X.821) in our case. The gene mutation has not been reported and was predicted to seriously affect the protein structure. According to a review of 59 cases of ERCC5 mutations, cerebrooculofacioskeletal syndrome (COFS) occurred in 16 cases, XP in 19 cases, and XP/CS in 24 cases. The incidence of physical retardation, mental retardation, peripheral neuropathy, magnetic resonance abnormalities and fundus/vision abnormalities in XP/CS patients was significantly higher than that in XP patients. In addition, patients with the XP/CS phenotype were more prone to appearance abnormalities, deafness, and epilepsy, and cheilitis and tumors were more common in patients with the XP phenotype, but the differences were not significant. XP/CS can cause abnormal liver function and even fatality, which should be given attention. ERCC5 mutation-related diseases were characterized by mild to severe clinical phenotypes. In addition to tumors, liver function should be considered in ERCC5-related diseases, and patients should be cautious with medication to avoid drug-induced liver injury.

Keywords

Cockayne syndrome / COFS / ERCC5 / liver function injury / Xeroderma pigmentosum

References

[1] FassihiH, SethiM, FawcettH, et al. Deep phenotyping of 89 xeroderma pigmentosum patients reveals unexpected heterogeneity dependent on the precise molecular defect. Proc Natl Acad Sci U S A. 2016; 113(9): E1236-E1245.

[2] ZhouEY, WangH, LinZ, et al. Clinical and molecular epidemiological study of xeroderma pigmentosum in China: a case series of 19 patients. J Dermatol. 2017; 44(1):71-75.

[3] SidwellRU, Sandison A, WingJ, et al. A novel mutation in the XPA gene associated with unusually mild clinical features in a patient who developed a spindle cell melanoma. Br J Dermatol. 2006; 155(1):81-88.

[4] OhKS, KhanSG, JaspersNG, et al. Phenotypic heterogeneity in the XPB DNA helicase gene (ERCC3): xeroderma pigmentosum without and with Cockayne syndrome. Hum Mutat. 2006; 27(11):1092-1103.

[5] DiGiovannaJJ, Patronas N, KatzD, AbanganD, Kraemer KH Xeroderma pigmentosum: spinal cord astrocytoma with 9-year survival after radiation and isotretinoin therapy. J Cutan Med Surg. 1998; 2(3):153-158.

[6] CalmelsN, GreffG, ObringerC, et al. Uncommon nucleotide excision repair phenotypes revealed by targeted high-throughput sequencing. Orphanet J Rare Dis. 2016; 11(1):26.

[7] OhKS, EmmertS, TamuraD, DiGiovanna JJ, KraemerKH. Multiple skin cancers in adults with mutations in the XP-E (DDB2) DNA repair gene. J Invest Dermatol. 2011; 131(3):785-788.

[8] AhmadA, EnzlinJH, BhagwatNR, et al. Mislocalization of XPF-ERCC1 nuclease contributes to reduced DNA repair in XP-F patients. PLoS Genet. 2010; 6(3):e1000871.

[9] VermeulenW, JaekenJ, JaspersNG, Bootsma D, HoeijmakersJH. Xeroderma pigmentosum complementation group G associated with Cockayne syndrome. Am J Hum Genet. 1993; 53:185-192.

[10] ZafeiriouDI, ThorelF, AndreouA, et al. Xeroderma pigmentosum group G with severe neurological involvement and features of Cockayne syndrome in infancy. Pediatr Res. 2001; 49(3):407-412.

[11] Le Van QuyenP, Calmels N, BonniereM, et al. Prenatal diagnosis of cerebro-oculo-facio-skeletal syndrome: report of three fetuses and review of the literature. Am J Med Genet. 2020; 182(5):1236-1242.

[12] ChikhaouiA, ElouejS, NabouliI, et al. Identification of a ERCC5 c.2333T>C (L778P) variant in two Tunisian Siblings with mild xeroderma pigmentosum phenotype. Front Genet. 2019; 10:111.

[13] WangT, XuCC, ZhouXP, et al. Novel germline ERCC5 mutations identified in a xeroderma pigmentosum complementation group G pedigree. JAAD Case Rep. 2015; 1(2):66-70.

[14] NorrisPG, HawkJL, AveryJA, Giannelli F. Xeroderma pigmentosum complementation group G--report of two cases. Br J Dermatol. 1987; 116(6):861-866.

[15] SoltysDT, RochaCR, LernerLK, et al. Novel XPG (ERCC5) mutations affect DNA repair and cell survival after ultraviolet but not oxidative stress. Hum Mutat. 2013; 34(3):481-489.

[16] SunZ, ZhangJ, GuoY, et al. Genotype-phenotype correlation of xeroderma pigmentosum in a Chinese Han population. Br J Dermatol. 2015; 172(4):1096-1102.

[17] MoriwakiS, Takigawa M, IgarashiN, et al. Xeroderma pigmentosum complementation group G patient with a novel homozygous missense mutation and no neurological abnormalities. Exp Dermatol. 2012; 21(4):304-307.

[18] EmmertS, SlorH, BuschDB, et al. Relationship of neurologic degeneration to genotype in three xeroderma pigmentosum group G patients. J Invest Dermatol. 2002; 118(6):972-982.

[19] JaekenJ, Klocker H, SchwaigerH, BellmannR, Hirsch-Kauffmann M, SchweigerM. Clinical and biochemical studies in three patients with severe early infantile Cockayne syndrome. Hum Genet. 1989; 83(4):339-346.

[20] SchaferA, Schubert S, GratchevA, et al. Characterization of three XPG-defective patients identifies three missense mutations that impair repair and transcription. J Invest Dermatol. 2013; 133(7):1841-1849.

[21] LalleP, Nouspikel T, ConstantinouA, ThorelF, Clarkson SG. The founding members of xeroderma pigmentosum group G produce XPG protein with severely impaired endonuclease activity. J Invest Dermatol. 2002; 118(2):344-351.

[22] MoriwakiS, Stefanini M, LehmannAR, et al. DNA repair and ultraviolet mutagenesis in cells from a new patient with xeroderma pigmentosum group G and cockayne syndrome resemble xeroderma pigmentosum cells. J Invest Dermatol. 1996; 107(4):647-653.

[23] ThorelF, Constantinou A, Dunand-SauthierI, et al. Definition of a short region of XPG necessary for TFIIH interaction and stable recruitment to sites of UV damage. Mol Cell Biol. 2004; 24:10670-10680.

[24] ZhangJ, ChengR, YuX, SunZ, LiM, YaoZ. Expansion of the genotypic and phenotypic spectrum of xeroderma pigmentosum in Chinese population. Photodermatol Photoimmunol Photomed. 2017; 33(1):58-63.

[25] HijaziH, SalihMA, HamadMH, et al. Pellagra-like condition is xeroderma pigmentosum/Cockayne syndrome complex and niacin confers clinical benefit. Clin Genet. 2015; 87(1):56-61.

[26] LehmannJ, Schubert S, SchaferA, et al. An unusual mutation in the XPG gene leads to an internal in-frame deletion and a XP/CS complex phenotype. Br J Dermatol. 2014; 171(4):903-905.

[27] YangY, YaoX, LuoY, et al. Identification of a novel mutation confirms phenotypic variability of mutant XPG truncations. Int J Dermatol. 2017; 56(7): e149-e151.

[28] SantiagoKM, CastroLP, NetoJPD, et al. Comprehensive germline mutation analysis and clinical profile in a large cohort of Brazilian xeroderma pigmentosum patients. J Eur Acad Dermatol Venereol. 2020; 34(10):2392-2401.

[29] RicottiR, NardoT, StrianoP, Stefanini M, OrioliD, BottaE. Phenotypic variability in xeroderma pigmentosum group G: an uncommon case with severe prenatal-onset Cockayne syndrome features. Clin Genet. 2018; 94(3-4):386-388.

[30] GrahamJM, Jr., Anyane-Yeboa K, RaamsA, et al. Cerebro-oculo-facio-skeletal syndrome with a nucleotide excision-repair defect and a mutated XPD gene, with prenatal diagnosis in a triplet pregnancy. Am J Hum Genet. 2001; 69(2):291-300.

[31] LaugelV, DallozC, TobiasES, et al. Cerebro-oculo-facio-skeletal syndrome: three additional cases with CSB mutations, new diagnostic criteria and an approach to investigation. J Med Genet. 2008; 45(9):564-571.

[32] JaspersNG, RaamsA, SilengoMC, et al. First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure. Am J Hum Genet. 2007; 80(3):457-466.

[33] MeiraLB, GrahamJM, Jr., GreenbergCR, et al. Manitoba aboriginal kindred with original cerebro-oculo- facio-skeletal syndrome has a mutation in the Cockayne syndrome group B (CSB) gene. Am J Hum Genet. 2000; 66(4):1221-1228.

[34] Muniesa-VargasA, TheilAF, Ribeiro-SilvaC, VermeulenW, LansH. XPG: a multitasking genome caretaker. Cell Mol Life Sci. 2022; 79(3):166.

[35] YangG, YangY, MaX, et al. Association of ERCC5 genetic polymorphisms with cirrhosis and liver cancer. Technol Cancer Res Treat. 2020; 19:1533033820943244.

[36] ZhengX, ChenK, LiuX, JiangG, LiuH. High expression of ERCC5 predicts a poor prognosis in hepatocellular carcinoma. Int J Clin Exp Pathol. 2018; 11:3664-3670.

RIGHTS & PERMISSIONS

2024 The Authors. Pediatric Discovery published by John Wiley & Sons Australia, Ltd on behalf of Children’s Hospital of Chongqing Medical University.